Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between the E-wave propagation index and left ventricular thrombus formation after ST-elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reply to: TFC ECG in arrhythmogenic cardiomyopathy: Inadequate mixture of criteria?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Looking beyond antiplatelet effect of P2Y12 inhibitors: is there anything to see?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Diagnostic findings and follow-up outcomes in relatives to young non-autopsied sudden death victims

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. 2020 ESC Guidelines for the management of adult congenital heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Biomarkers and Their Relation to Cardiac Function Late After Peripartum Cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Heart failure (HF) is widely associated with a median survival of 5 years. However, population level data on survival and HF progression has been limited for key subgroups. We assessed survival and HF progression, defined as hospitalization or outpatient diuretic intensification in patients ≤70 years without severe comorbidity, who received relevant medical therapy. Methods: From administrative registers, we identified all Danish patients ≤70 years diagnosed with HF 2000–2012 without severe comorbidity, survived for 120 days to receive angiotensin converting enzyme inhibitors (ACE-I)/angiotensin receptor blocker (ARB) and beta blocker. Risk of death or progression of HF was assessed with Kaplan-Meier and Aalen Johansen estimators, respectively. Cox regression models were used to identify factors associated with risk of death. Results: We included 19,985 patients, median age 61, 25% women - 1/3 of all HF patients ≤70 years. We excluded 237 patients who died within 120 days and 21,065 due to severe comorbidity. Five-year cumulative incidence of all-cause death was 14% (95%-confidence interval [CI]:13–14). Risk of death was increased for patients first diagnosed in hospital compared to outpatient clinics (hazard ratio: 1.51, 95%-CI:1.38–1.65, p < 0.001). Five-year cumulative incidence of HF hospitalization: 18% (95%-CI, 18–19) and intensification of diuretic therapy: 14% (95%-CI, 14–15). Conclusions: In patients ≤70 years without severe comorbidity, five-year mortality was only 14% and almost 2/3 were alive after 5 years without evident HF progression. Discussion of prognosis should be tailored to age and health status to provide realistic expectations for patients newly diagnosed and treated with recommended therapies for HF.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cardiology
Vol/bind305
Sider (fra-til)106-112
Antal sider7
ISSN0167-5273
DOI
StatusUdgivet - 15 apr. 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 59211142